ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention

Song, Kai; Jin, Xuan; Kim, Moo-Hyun*; Li, Jia-Xin; Jin, Cai-De; Yuan, Song-Lin; Song, Zhao-Yan; Jin, En-Ze; Lee, Kwang-Min; Lim, Kyung-Hee; Cho, Young-Rak广州医学院; 哈尔滨医科大学
Journal of Clinical Medicine2022-5DOI: 10.3390/jcm11092480
2被引9阅读
引用收藏
分享

摘要

Background: East Asian patients receiving treatment with the potent P2Y12 inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Methods: This study investigated differences in OPR rates with reduced doses of prasugrel (n = 38) or ticagrelor (n = 40) for maintenance therapy in 118 Korean ACS patients who had undergone PCI, in comparison to conventional-dose clopidogrel (n = 40). We assessed drug responses at one- and three-months post-PCI with VerifyNow and multiple electrode aggregometry assays. Results: At the one-month period, patients receiving standard-dose prasugrel or ticagrelor had lower platelet reactivity as determined by the three assays than those receiving the conventional dose of clopidogrel (VN: p = 0.000; MEA: p = 0.000; LTA: p = 0.000). At the 3-month point, platelet reactivity was lower in those receiving reduced-dose prasugrel or ticagrelor than the clopidogrel-treated patients (VN: p = 0.000; MEA: p = 0.012; LTA: p = 0.002). Prasugrel resulted in significantly lower platelet inhibition than ticagrelor as determined by VN and LTA (VN: p = 0.000; LTA: p = 0.003). At three months, there was a significant overall difference in OPR among the three groups when measured by VN (p < 0.001), but not when measured by MEA (p = 0.596). OPR in the reduced-dose prasugrel group was not significantly different to the clopidogrel group at three months (VN: p = 0.180; MEA: p = 0.711). OPR in the reduced-dose ticagrelor group was similar to clopidogrel as determined by MEA at three months, but was different when assessed by VN (VN: p = 0.000; MEA: p = 0.540). Compared to standard-dose, the reduced-dose prasugrel OPR rate was significantly increased (VN: p = 0.008; MEA: p = 0.020). Conclusions: OPR values for reduced-dose prasugrel and conventional-dose clopidogrel at three months were similar but higher than for reduced-dose ticagrelor as determined by VN, but no differences were noted by MEA. The MEA assay might have less sensitivity and consistency than the VN assay. Further studies are needed to explore this discrepancy.

学科与关键词

关键词
optimal platelet reactivityVerifyNowmultiple electrode aggregometrylight transmittance aggregometry
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Journal of Clinical Medicine
发表日期
2022-05
卷期
第 11 卷, 第 9 期
页码
2480
DOI
10.3390/jcm11092480
期刊等级
3区
成果收录
SCIE
资助标注
Korean Society of Cardiology [201605-02]

作者

  • S

    Song, Kai (第一作者)

    guangzhou med univ

  • J

    Jin, Xuan

查看全部 11 位作者收起作者
  • K

    Kim, Moo-Hyun (通讯)

  • L

    Li, Jia-Xin

    harbin med univ

  • J

    Jin, Cai-De

  • Y

    Yuan, Song-Lin

  • S

    Song, Zhao-Yan

    harbin med univ

  • J

    Jin, En-Ze

    harbin med univ

  • L

    Lee, Kwang-Min

  • L

    Lim, Kyung-Hee

  • C

    Cho, Young-Rak

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417